非瓣膜性房颤患者华法林起始阶段缺血性卒中风险:基于大型保险数据库的评估
本研究利用MarketScan保险索赔数据库,比较非瓣膜性房颤患者启动华法林与未启动华法林者30天内缺血性卒中发生率。多因素回归显示华法林与随访时间存在显著交互,30天内调整HR 1.46(95%CI 0.80-2.65),之后0.70(0.57-0.85)。结论提示华法林起始后短期内卒中风险可能轻度增加。
要点
- 华法林起始后30天内缺血性卒中风险可能轻度升高,调整HR 1.46(95%CI 0.80-2.65)。
- 30天后华法林显著降低卒中风险,调整HR 0.70(95%CI 0.57-0.85)。
- 临床应关注华法林起始早期卒中风险,但研究样本量有限需谨慎解读。
核心结论
- 华法林起始后30天内与后续时期的效应 qualitatively 不同,提示起始后短期内卒中风险可能轻度增加。
主要发现
- 华法林组与对照组临床特征相似,但CHADS2评分较高(1.26 vs 1.19)。
- 起始后30天缺血性卒中率华法林组1.47%/年(27/1836) vs 对照组0.98%/年(18/1837),P=0.18。
- 多因素回归显示随访时间与华法林使用存在显著交互,调整HR(95%CI)30天内1.46(0.80-2.65),之后0.70(0.57-0.85)。
临床怎么用
- 临床启动华法林时应意识到起始后30天内卒中风险可能轻度升高,但后续获益显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Stroke risk may increase shortly after warfarin initiation in nonvalvular atrial fibrillation patients. Because of the brief period and limited number of events, large samples are needed to study this effect. We compared 30-day rates of ischemic stroke between nonvalvular atrial fibrillation patients initiating warfarin to nonwarfarin comparators using an insurance claims database. METHODS: We identified nonvalvular atrial fibrillation patients via 1 inpatient/2 outpatient diagnosis claims from the MarketScan database, January 1, 2009, to December 31, 2010. We studied patients initiating warfarin using prescription claims and 1:1 matched 22 669 initiators to comparators based on age, sex, diagnosis date, and warfarin propensity score. Follow-up began on initiation date; patients were censored at discontinuation/switch of therapy, disenrollment, or end of the study. The median follow-up was 415 days. Cox regression was used to study differences in ischemic stroke risks between warfarin initiators and comparators while controlling for important prognostic factors. RESULTS: Warfarin initiators were generally similar to comparators in clinical features but had higher CHADS2 scores (1.26 versus 1.19). The first 30-day ischemic stroke rate was higher among warfarin initiators than comparators (1.47%/y (27/1836) versus 0.98%/y (18/1837); P=0.18) but lower subsequently (0.81%/y [134/16 543] versus 1.09%/y [406/37 248]; P=0.002). Multivariable regression confirmed a significant interaction between follow-up and warfarin use with the adjusted hazard ratios (95% confidence intervals) for warfarin/comparator as 1.46 (0.80-2.65) in the first 30 days and 0.70 (0.57-0.85) afterward. CONCLUSIONS: Warfarin effect was qualitatively different in the first 30 days after initiation than subsequently. This is consistent with a modest increase in stroke risk occurring briefly after starting warfarin.
引用
- Tepper PG, Liu X, Hamilton M, et al. Ischemic Stroke in Nonvalvular Atrial Fibrillation at Warfarin Initiation: Assessment via a Large Insurance Database. Stroke. 2017. PMID: 28446621. doi:10.1161/STROKEAHA.116.015535
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。